{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rubeola",
    "query": {
      "condition": "Rubeola"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rubeola&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-21T22:23:13.329Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06855160",
      "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Candidate varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 911,
      "start_date": "2025-04-17",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06855160"
    },
    {
      "nct_id": "NCT00013871",
      "title": "Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis B",
        "Measles",
        "Pneumococcal Infections",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Measles-Mumps-Rubella Vaccine (Live)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Vaccine, Polyvalent (23-valent)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal Conjugate Vaccine, Heptavalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 300,
      "start_date": null,
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00013871"
    },
    {
      "nct_id": "NCT00450814",
      "title": "Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2006-11-30",
      "completion_date": "2019-11-20",
      "has_results": true,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450814"
    },
    {
      "nct_id": "NCT02058563",
      "title": "Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rubella",
        "Mumps",
        "Measles"
      ],
      "interventions": [
        {
          "name": "Priorix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 996,
      "start_date": "2014-07-01",
      "completion_date": "2015-09-17",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058563"
    },
    {
      "nct_id": "NCT02700230",
      "title": "Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Peripheral Nerve Sheath Tumor",
        "Neurofibromatosis Type 1",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Single Photon Emission Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasound Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-03-22",
      "completion_date": "2024-04-17",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02700230"
    },
    {
      "nct_id": "NCT01621802",
      "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Measles-Mumps-Rubella"
      ],
      "interventions": [
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Kinrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ProQuad",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 4011,
      "start_date": "2012-06-21",
      "completion_date": "2015-11-09",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Benton, Arkansas + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01621802"
    },
    {
      "nct_id": "NCT00138255",
      "title": "Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Measles",
        "Mumps",
        "Rubella",
        "Varicella"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "16 Months",
        "sex": "ALL",
        "summary": "Up to 16 Months"
      },
      "enrollment_count": 32,
      "start_date": "2004-06",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138255"
    },
    {
      "nct_id": "NCT01846091",
      "title": "Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "Head and Neck Squamous Cell Carcinoma",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Recurrent Head and Neck Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-04-09",
      "completion_date": "2019-11-26",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846091"
    },
    {
      "nct_id": "NCT01369394",
      "title": "Making Decisions About the Measles-Mumps-Rubella Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Measles",
        "Mumps",
        "Rubella",
        "MMR Vaccination"
      ],
      "interventions": [
        {
          "name": "Behavioral: Computer-based tailoring system",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2011-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2014-12-10",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369394"
    },
    {
      "nct_id": "NCT00871117",
      "title": "Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tetanus",
        "Acellular Pertussis",
        "Diphtheria"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals'Kinrix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck and Company's MMRII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Merck and Company's Varivax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 478,
      "start_date": "2009-03-31",
      "completion_date": "2010-06-15",
      "has_results": true,
      "last_update_posted_date": "2018-08-22",
      "last_synced_at": "2026-07-21T22:23:13.329Z",
      "location_count": 11,
      "location_summary": "Antioch, California • Daly City, California • Hayward, California + 7 more",
      "locations": [
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871117"
    }
  ]
}